The United States Food and Drug Administration has approved use of the combination of BRAF and MEK inhibitors for BRAF V600E mutant malignant melanomas, anaplastic thyroid cancers, non-small cell lung cancers, pediatric low grade gliomas requiring systemic therapy and metastatic unresectable solid tumors as a tissue agnostic treatment. The gene discussed is MAP2K7; the disease is thyroid gland undifferentiated (anaplastic) carcinoma.